Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
Prog Cardiovasc Dis
; 82: 113-124, 2024.
Article
em En
| MEDLINE
| ID: mdl-38246305
ABSTRACT
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized cause of heart failure (HF). ATTR-CM can lead to a number of cardiovascular manifestations including HF, rhythm disturbances, and valvular disease that ultimately limit quality of life and prognosis. Due to advances in diagnostic modalities and therapeutic options, the prevalence of ATTR-CM is rising. There are several classes of medications under active investigation, though most therapies are most efficacious if instituted early on in the disease course. As such, early clinical recognition and prompt diagnosis are crucial to improving disease related outcomes. In this review, we highlight clinical manifestations of ATTR-CM as well as contemporary diagnostic and treatment approaches to the disease.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neuropatias Amiloides Familiares
/
Insuficiência Cardíaca
/
Cardiomiopatias
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article